^
PIK3CA V955G
Colorectal Adenocarcinoma
cetuximab
Resistant: C3 – Early Trials
ALK fusion
Colorectal Adenocarcinoma
ceritinib
Sensitive: C3 – Early Trials
KRAS mutation
Colorectal Adenocarcinoma
ceritinib
Resistant: C3 – Early Trials
EWSR1 mutation
Colorectal Adenocarcinoma
sintilimab + fruquintinib
Resistant: C3 – Early Trials
PD-L2 overexpression
Colorectal Adenocarcinoma
PD-L1 inhibitor + PD-L2 inhibitor
Sensitive: D – Preclinical
KRAS G13D
Colorectal Adenocarcinoma
ASN007
Sensitive: D – Preclinical